BD Diagnostics Collaborate With Bruker to Improve Microbial Identification
By LabMedica International staff writers Posted on 11 Oct 2010 |
BD Diagnostics (Sparks, MD, USA) announced an international codevelopment and comarketing collaboration with Bruker Daltonics Inc. (Billerica, MA, USA).
BD Diagnostics is a segment of the Becton, Dickinson and Company (Franklin Lakes, NJ, USA), and Bruker Daltonics is a subsidiary of Bruker Corporation (Billerica, MA, USA). The collaboration will promote an emerging, integrated approach to bacterial and fungal identification and antimicrobial susceptibility testing.
Through this collaboration, identification of microorganisms will be performed with the Bruker MALDI Biotyper, a mass spectrometry-based proteomic "fingerprinting” system specifically configured for rapid identification of bacteria and fungi. BD and Bruker intend to combine the MALDI Biotyper microbial ID system with automated antimicrobial susceptibility testing on the BD Phoenix Microbiology System. The MALDI Biotyper and BD EpiCenter software integration will be further developed to optimize workflows for rapid MALDI Biotyper pathogen identification directly on positive blood cultures from the leading BD BACTEC blood culture system. This rapid blood culture-to-ID workflow is supported by Bruker's new MALDI Sepsitype consumables kit.
Microbial identification and antimicrobial susceptibility testing is the end-point of the major work a microbiology laboratory performs on a daily basis. After culturing and isolating bacteria and fungi from patient specimens, organisms need to be identified and tested to determine which drugs will inhibit or stop their growth. The Bruker MALDI Biotyper allows highly accurate, rapid, and cost-effective identification through a process in which organisms are identified by the unique spectrum of the major proteins and peptides that constitute their makeup.
Frank Laukien, Ph.D., President and CEO of Bruker Corporation, said, "Working with a worldwide leader in microbiology and infectious disease will enable us to further expand the groundbreaking MALDI Biotyper molecular method for microbial identification to its full extent.”
Related Links:
BD Diagnostics
Bruker Daltonics Inc.
Becton, Dickinson and Company
Bruker Corporation
BD Diagnostics is a segment of the Becton, Dickinson and Company (Franklin Lakes, NJ, USA), and Bruker Daltonics is a subsidiary of Bruker Corporation (Billerica, MA, USA). The collaboration will promote an emerging, integrated approach to bacterial and fungal identification and antimicrobial susceptibility testing.
Through this collaboration, identification of microorganisms will be performed with the Bruker MALDI Biotyper, a mass spectrometry-based proteomic "fingerprinting” system specifically configured for rapid identification of bacteria and fungi. BD and Bruker intend to combine the MALDI Biotyper microbial ID system with automated antimicrobial susceptibility testing on the BD Phoenix Microbiology System. The MALDI Biotyper and BD EpiCenter software integration will be further developed to optimize workflows for rapid MALDI Biotyper pathogen identification directly on positive blood cultures from the leading BD BACTEC blood culture system. This rapid blood culture-to-ID workflow is supported by Bruker's new MALDI Sepsitype consumables kit.
Microbial identification and antimicrobial susceptibility testing is the end-point of the major work a microbiology laboratory performs on a daily basis. After culturing and isolating bacteria and fungi from patient specimens, organisms need to be identified and tested to determine which drugs will inhibit or stop their growth. The Bruker MALDI Biotyper allows highly accurate, rapid, and cost-effective identification through a process in which organisms are identified by the unique spectrum of the major proteins and peptides that constitute their makeup.
Frank Laukien, Ph.D., President and CEO of Bruker Corporation, said, "Working with a worldwide leader in microbiology and infectious disease will enable us to further expand the groundbreaking MALDI Biotyper molecular method for microbial identification to its full extent.”
Related Links:
BD Diagnostics
Bruker Daltonics Inc.
Becton, Dickinson and Company
Bruker Corporation
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus